Swiss National Bank
AKCA

Swiss National Bank’s Akcea Therapeutics Inc AKCA Stock Holding History

Swiss National Bank’s Portfolio AKCA Stock Details AKCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-45,100
Closed -$818K – 2547
2020
Q3 		$818K Hold
45,100
– – ﹤0.01% 2195
2020
Q2 		$618K Buy
45,100
+8,700
+24% +$134K ﹤0.01% 2326
2020
Q1 		$521K Buy
36,400
+800
+2% +$13.1K ﹤0.01% 2158
2019
Q4 		$603K Buy
35,600
+800
+2% +$14.9K ﹤0.01% 2367
2019
Q3 		$536K Buy
34,800
+1,500
+5% +$32K ﹤0.01% 2342
2019
Q2 		$781K Buy
33,300
+800
+2% +$19.8K ﹤0.01% 2247
2019
Q1 		$921K Buy
32,500
+2,200
+7% +$64.1K ﹤0.01% 2108
2018
Q4 		$913K Buy
30,300
+2,000
+7% +$56.1K ﹤0.01% 2054
2018
Q3 		$991K Hold
28,300
– – ﹤0.01% 2144
2018
Q2 		$671K Hold
28,300
– – ﹤0.01% 2358
2018
Q1 		$725K Hold
28,300
– – ﹤0.01% 2262
2017
Q4 		$491K Buy
+28,300
New +$555K ﹤0.01% 2414

Swiss National Bank's AKCA Position: Q4 2020 in Review

Swiss National Bank sold out of Akcea Therapeutics Inc (AKCA) in Q4 2020, closing a stake of 45,100 shares — an estimated $818K sold.

Swiss National Bank first reported a position in AKCA in Q4 2017 and held it in 12 quarters. The position peaked at $991K in Q3 2018. 0 funds tracked by Wall St. Rank hold AKCA as of Q4 2020.

  • Swiss National Bank reported no remaining Akcea Therapeutics Inc position as of Q4 2020 after selling out during the quarter.
  • Swiss National Bank sold 45,100 Akcea Therapeutics Inc shares in Q4 2020, an estimated $818K.
  • Swiss National Bank first reported a position in Akcea Therapeutics Inc in Q4 2017 and held it in 12 quarters.
  • Swiss National Bank's Akcea Therapeutics Inc position peaked at $991K in Q3 2018.
  • 0 funds tracked by Wall St. Rank held Akcea Therapeutics Inc as of Q4 2020.

Based on Swiss National Bank's 13F filing for Q4 2020, filed 5 Feb 2021.